Can a Covid Vaccine Be Too Perfect?
Bloomberg Businessweek|November 09, 2020
The lack of serious side effects in China’s big trials is raising concerns about transparency
By Rachel Chang, Michelle Fay Cortez, and Anjali Cordeiro, with Jinshan Hong and Riley Griffin

Chinese companies’ seemingly remarkable progress has them leading the race for a coronavirus vaccine. Their speedy ascent has been unhindered by common scientific setbacks being reported by Western rivals, however, raising questions about how stringently they’re vetting results and reporting potential safety issues.

China has the largest number of candidates in late-stage vaccine trials, and its shots could be used by millions worldwide because President Xi Jinping has pledged to share successful ones overseas. But there is concern about Chinese developers’ standards and safeguards because some of their vaccines are being distributed in the country under an emergency use program before getting full regulatory approval.

AstraZeneca Plc and Johnson & Johnson temporarily halted testing earlier this year in the U.K. and the U.S., respectively, after a single participant in each trial got sick. In contrast, China’s science ministry has said its companies have inoculated about 60,000 volunteers in final-stage trials, but there have been no reports of serious adverse events.

One front-runner, China National Biotec Group Co., has said it’s vaccinated hundreds of thousands of people under the emergency use program, a sign of how widely Chinese shots are being administered without reports of serious adverse events. Yet scientists say the discovery of health problems is inevitable when so many people of all ages and with varying conditions are tested—even if the vaccine isn’t causing the illness.

Continue reading your story on the app

Continue reading your story in the magazine

MORE STORIES FROM BLOOMBERG BUSINESSWEEKView All

Test All of Minnesota? You Betcha

Minnesota is setting an example for other states and the federal government. If anyone is interested

10+ mins read
Bloomberg Businessweek
January 18, 2021

The Cult of Positivity

WHY BLIND OPTIMISM IS DRIVING US NUTS

7 mins read
Bloomberg Businessweek
January 18, 2021

SPOTIFY'S PODCAST POWER PLAY

The company is staking its future on converting music listeners to podcast fans and has become the favorite to own the industry—for better or worse

10+ mins read
Bloomberg Businessweek
January 18, 2021

Why the U.S. Senate Is Broken

Adam Jentleson argues that toxic partisanship rose when the filibuster became a cudgel

6 mins read
Bloomberg Businessweek
January 18, 2021

America's Missing Workers

Near-record levels of absenteeism could be hampering the recovery

4 mins read
Bloomberg Businessweek
January 18, 2021

The Electric Truck That Couldn't

In the past six months, Nikola has faced an SEC probe, lost partners, and seen its shares tank

5 mins read
Bloomberg Businessweek
January 18, 2021

WALL STREET SOUTH

Florida braces for a gold-plated makeover as finance rethinks its attachment to New York

6 mins read
Bloomberg Businessweek
January 18, 2021

Yet Another Winning Year For Hindsight Capital

With the miserable year of 2020 over, it’s time to return to the offices of Hindsight Capital LLC.

2 mins read
Bloomberg Businessweek
January 11, 2021

Social Media Hits Mute After the Capitol Riot

Facebook and Twitter can block the president, but his supporters will move on

4 mins read
Bloomberg Businessweek
January 18, 2021

Where to Go in 2021

THE GLOBAL ECONOMY NEEDS A TRAVEL REBOUND. YOU COULD USE ONE, TOO. AS SOON AS IT’S SAFE, MAKE YOUR PLANS COUNT WITH 24 IDEAS TO HELP HEAL THE WORLD ONE SMALL STEP AT A TIME

10+ mins read
Bloomberg Businessweek
January 11, 2021